Biogen Reports Phase 2b Data for Avacopan in Melanoma

Biogen today announced Phase 2b results for avacopan in patients with melanoma. The study demonstrated that avacopan improves functional outcomes compared to standard of care or placebo. These results provide important insights into the treatment of melanoma and support the continued development of avacopan in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.